NCT06360861View on ClinicalTrials.gov

Evaluate the Safety and Feasibility of Allogeneic Mesenchymal Stem Cells in Patients With Multiple Sclerosis

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

July 23, 2019

Primary Completion Date

March 4, 2024

Study Completion Date

March 6, 2024

Conditions
Multiple SclerosisSecondary-Progressive Multiple SclerosisMesenchymal Stem Cells
Interventions
BIOLOGICAL

Allogenic placenta derived mesenchymal stem cells

Allogenic placenta derived mesenchymal stem cells, 3 million cells/kg body weight via intravenous injection.

Trial Locations (1)

Unknown

Tehran University of Medical Sciences,Tehran, Iran, Tehran

All Listed Sponsors
lead

Tehran University of Medical Sciences

OTHER

NCT06360861 - Evaluate the Safety and Feasibility of Allogeneic Mesenchymal Stem Cells in Patients With Multiple Sclerosis | Biotech Hunter | Biotech Hunter